Serum pepsinogen I and pepsinogen II levels and its ratio in patients with gastric cancer: a case control study

Amal Abraham, T. U. Girish, B. J. Sharathchandra, Subbarao V. Madhunapantula, Manish Kumar Yadav, Santosh Raja Erabati


Background:Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The incidence of gastric cancer is found to increase in the developing countries like India due to change in the life style like having smoked food containing nitrates, smoking , alcoholism and consumption of large amount of red chillies. The objective of this study was to measure the serum pepsinogen I and pepsinogen II levels and its ratio in gastric cancer patients admitted in JSS hospital and Bharath Cancer Centre during the period October 2012 to October 2014 and to compare with controls.

Methods: 80 patients - 40 patients with gastric cancer and 40 patients control were studied. Serum pepsinogen I (PG I) and pepsinogen II (PG II) levels were measured using ELISA.

Results:The mean PG I levels for cancer patients and controls were 93.98μg/dl and 82.156μg/dl respectively, the mean PG II levels were 42.67 μg/dl and 18.79 μg/dl respectively. The PG I/II ratio in cancer patients is 2.75 and 5.73 in controls, the ratio was significantly lower in cancer patients (P value significant).

Conclusions:The ultimate aim in the management of carcinoma stomach is the early detection of the disease. At present endoscopy and biopsy is the gold standard of diagnosis. Different screening tools are under development for the diagnosis of the disease. Our study evaluates a test which can be recommended as an alternative to the diagnosis of gastric carcinoma at an early stage.


Serum pepsinogen I, Serum pepsinogen II, Carcinoma stomach

Full Text:



Dathan ML, Mohandas N, Jayarajan TK. Tobacco chewing - a risk factor for gastric cancer. Indian J Surg. 1996:285-8.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - first cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735.

Parthasarathy G, Maroju NK, Ananthakrishnan N, Sridhar MG. Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach. Trop Gastroenterol. 2007;28(4):166-70.

Kitahara F, Kojima Y, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693-7.

Samloff IM. Pepsinogens, pepsins, and pepsin inhibitors. Gastroenterology. 1971;60:586-604.

Samloff IM. Immunologic studies of human group I pepsinogens. J Immunol. 1971;106:962-8.

Konishi N, Matsumoto K, Hiasa Y, Kitahori Y, Hayashi I, Matsuda H. Tissue and serum pepsinogen I and II in gastric cancer identified using immunohistochemistry and rapid ELISA. F Clinpathol. 1995;48:364-7.

Uemura N, Okamato S, Yammoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter infection and the development of gastric cancer. N Engl J Med. 2001;345:11:784-9.

The Eurogast study group. An international association between helicobacter pylori infection and gastric cancer. Lancet. 1993;341(8857):1359-62.

Forman D, Sitas F, Newell DG, Stacey AR, Boreham J, Peto R, et al. Geographic association of helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer. 1990;46:608-11.

Aggarwal SP, Walia DJ, Chawla LS. Serum pepsinogen levels in patients with gastroduodenal lesions. J Assoc Physicians India. 1994;42(9):713-4.

Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Japonica. 1987;22:133-41.

Ubukata H, Konishi S, Nakachi T, Motohashi G, Goto Y, Watanabe Y, et al. Characteristics of the serum pepsinogen (PG) test, and the relationship between PG test results and gastric cancer outcomes. Scand J Surg. 2010;99(4):201-7.

Hattori Y, Tashiro H, Kawamoto T, Kodama Y. sensitivity and specificity of mass screening for gastric cancer using the measurement for serum pepsinogens. Japonica J Cancer Res. 1995;86:1210-5.

Mario DR, Altamiro CP, Carlos L, Barbosa J, Guilherme M, Dias LM, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal - type gastric adenocarcinoma. Neoplasia. 2004;6(5):449-56.